Bavarian Nordic A/S has announced that Health Canada has accepted its New Drug Submission for the review of its chikungunya vaccine candidate, CHIKV VLP. This marks a significant step in the company's efforts to expand global access to the vaccine, which has already received approvals in the US, EU, and UK. The submission is based on data from two successful phase 3 clinical trials involving over 3,500 participants, demonstrating high efficacy and safety. Pending approval, the vaccine could become available to Canadians seeking protection against chikungunya virus as early as the first half of 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。